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SDS variation in IGHD patients and 15.9% of height SDS vari-
ation in controls.  Conclusion:  GH1 Promoter SNPs 6, 8 and 9 
were associated with height and IGF-1 levels among pa-
tients, and SNPs 6 and 11 with height in controls. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Human postnatal growth is determined by the inter-
action of various genetic and environmental factors, and 
results from the lengthening of bones via cellular divi-
sions, which is mainly regulated by human growth hor-
mone (GH). GH, secreted by the somatotrophs of the an-
terior pituitary gland, is a protein of 191 amino-acids (22 
kDa) with 2 disulfide bridges, which are important for its 
structure and bioactivity. GH synthesis and secretion are 
regulated by several hormones, reviewed by Goldenberg 
and Barkan  [1] . GH releasing hormone is produced in the 
hypothalamus and stimulates GH production via bind-
ing to the GHRH receptor (GHRHR), which is located in 
the anterior pituitary. GH production is negatively regu-
lated by the somatotropin release inhibiting factor, or so-
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 Abstract 
 Background/Aims: Expression of the human growth hor-
mone (GH) gene  (GH1)  is regulated by a locus control region 
(LCR) and the highly polymorphic  GH1  promoter. We ana-
lyzed  GH1  LCR/promoter single nucleotide polymorphisms 
(SNPs) in patients with isolated growth hormone deficiency 
(IGHD) in relation to clinical data.  Methods: We directly se-
quenced the  GH1  LCR/promoter of 62 Dutch IGHD patients 
without mutations or deletions in  GH1  or  GHRHR and of 72 
controls with normal height. We related  GH1  LCR/promoter 
SNPs to height, serum insulin-like growth factor 1 (IGF-I) lev-
els and response to GH treatment.  Results: In IGHD patients, 
promoter SNPs 6, 8 and 9 were associated with height and 
IGF-1 levels. In controls, SNPs 6 and 11 were associated with 
height. Homozygosity for the minor allele of SNP 9, associ-
ated with lower IGF-I levels in patients, was significantly 
more frequent among patients than among controls. Geno-
types based on SNPs 6, 8, 9 and 11 explained 10.8% of IGF-I 
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matostatin, and by insulin-like growth factor 1 (IGF-I), 
the end product of GH’s action.
 Mutations in the genes encoding GH and GHRHR 
( GH1  and  GHRHR,  respectively) can cause isolated 
growth hormone deficiency (IGHD) types IA, IB (OMIM 
No. 262400) and II (OMIM No. 173100). The frequency 
of  GH1  and  GHRHR  mutations in IGHD patients varies 
between 0 and 32% among different countries  [2–7] . 
Thus, in the best of cases, mutations in the coding regions 
of  GH1  and  GHRHR  are only detected in one third of the 
IGHD patients.
 GH1  is located in the human GH cluster, in which 5 
genes are situated on chromosome 17. Human GH ( GH1 ) 
lies at the 5  end of the cluster and is mainly expressed in 
pituitary somatotrophs. The remaining 4 genes, placental 
growth hormone ( GH2 ) and 3 chorionic somatomammo-
tropins  (CS1, CS2,  and the pseudogene  CS5  or  CSHP1) , 
are only expressed in the placenta. 
 The expression of  GH1  is regulated by a locus control 
region (LCR), located 14.5–32 kb upstream of the gene  [8] 
and by the  GH1  promoter. To date, 3 single nucleotide 
polymorphisms (SNPs) have been reported in the LCR 
 [9] , while the  GH1  promoter is highly polymorphic  [9–
14] . 
 Although, in general, SNPs do not necessarily cause 
disease, they have been associated with susceptibility to 
diseases  [15–17] and to environmental toxins  [18] by af-
fecting splicing  [19] , allelic expression  [20] , nonsense-me-
diated mRNA decay  [21] or transcription factor binding 
 [22] .  GH1  promoter SNPs have been associated with 
height  [9, 10, 12] , bone density, bone loss and fetal growth 
restriction  [23, 24] . In addition, some  GH1  promoter 
SNPs have been associated with breast and colorectal 
cancer  [13, 25–28] . Two promoter SNPs have been studied 
in relation to GH and/or IGF-I levels in patients with 
varying degrees of GH deficiency  [11, 12] .
 The Dutch Hypothalamic and Pituitary Gene Study is 
a nation-wide multicenter study investigating genetic and 
other causes of ‘idiopathic’ growth hormone deficiency 
in the Dutch GH deficiency population. In order to ex-
plain the variability in our IGHD patients’ phenotypes 
and their variable response to GH treatment, we analyzed 
 GH1  LCR/promoter sequence variations in IGHD pa-
tients and looked for associations of these variations with 
height, serum IGF-I levels and height increases during 
the 1st year of GH treatment. We compared the data with 
those of a healthy Dutch control group. Since Hasegawa 
et al.  [12] related the SNP ‘P1’ in  GH1  intron 4 (dbSNP 
2665802) with height, GH and IGF-I levels, we also in-
cluded this polymorphism in our analysis. 
 Patients and Methods 
 We included 62 Dutch Caucasian patients diagnosed with 
IGHD based on a scoring system including height SDS (HSDS), 
maximum GH levels, IGF-I and IGFBP-3 SDS without mutations 
or deletions in  GH1  or  GHRHR  [29] . Patients’ clinical data were 
available from the Dutch National Registry of Growth Hormone 
Treatment, where auxologic and laboratory parameters have been 
documented. 
 GH and IGF-I measurements were centrally performed in 1 
laboratory with published reference values  [30] for 80% of the pa-
tients. For the remaining 20%, the laboratory-specific reference 
values for IGF-I were used to calculate the SDS. We obtained ap-
proval from the medical ethics committees of all participating 
hospitals. Informed consent was obtained from all participating 
patients or their parents, if the patients were aged less than 18 
years. Seventy-two healthy Caucasian Dutch young adults with a 
height SDS between –2 and +2 agreed to participate in DNA anal-
ysis as control subjects. 
 Genomic DNA, extracted from peripheral blood according to 
standard procedures, was used for direct sequencing of the  GH1 
 LCR/promoter using an ABI 3100 Sequencer. A 1,231-bp frag-
ment including the promoter of  GH1  was amplified using forward 
primer 5  -GGGAGCCCCAGCAATGC-3  and reverse primer 5  -
TCTGCCTGCATTTTCGCTTCG-3  by Touchdown PCR, in-
cluding denaturation for 10 min at 95 ° C, amplification at 68–
61°C decreasing the annealing temperature by 1 ° C every 2nd cy-
cle and 25 subsequent cycles at 61°C, followed by a 7-min extension 
at 72 ° C. This fragment was sequenced by forward primers 5  -
GGGAGCCCCAGCAATGC-3  and 5  -CTGTCTGGTGGGTG-
GAGGTTAAA-3  , and reverse primers 5  -CACATTCAGAAG-
CCCCAAAC-3  and 5  -ACCCAACTTGTCCTCTCTTTA-3  . 
 Since Hasegawa et al.  [12] related the SNP ‘P1’ (IVS4 +90 T/A, 
dbSNP 2665802) in  GH1  intron 4 with height, GH and IGF-I levels, 
we included this polymorphism in our analysis. P1 genotypes were 
available for patients who had participated in the genetic screening 
of the coding regions of  GH1  and  GHRHR  as part of the Hypotha-
lamic and Pituitary Gene Study  [29] . In these patients, exon 4 and 
intron 4 had been PCR-amplified with forward primer 5  -CCGT-
GAGTGGATGCCTTCTC-3  and reverse primer 5  -GTGAGT-
TCTCTTGGGTCAGG-3  (annealing temperature 57.7 ° C), and 
the fragment had been screened by WAVE dHPLC at 62.1 and 
62.6 ° C, which were shown to accurately detect the P1 variant  [29] . 
 We used the  GH1  gene nucleotide sequence obtained from 
GenBank (Accession No. J03071) as a control and we numbered 
the SNPs according to Horan et al.  [9] . We obtained the reference 
LCR sequence from GenBank (Accession No. AF010280) and 
used LCR numbering according to Jin et al.  [31] . Of the LCR/pro-
moter SNPs, linkage disequilibrium represented by R 2 and D’ was 
analyzed using Haploview  [32] .
 The associations between genetic and clinical parameters were 
analyzed by means of ANOVA and   2 tests using SPSS Version 11.0. 
Response to GH treatment was defined as the increase in HSDS 
during the 1st year of GH treatment. The normality of the distribu-
tion of all analyzed parameters was assessed with the Kolmogorov-
Smirnov and Shapiro-Wilk tests. When expected cell counts for 
comparison of genotype frequencies between patients and controls 
were below 5, we used Fisher’s exact test instead of the   2 test. Pa-
rameters that were not normally distributed were analyzed using 
the nonparametric Kruskall-Wallis test instead of ANOVA.
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 Results 
 All LCR/promoter SNPs conformed with the Hardy-
Weinberg equilibrium according to a   2 test (p  1 0.05) 
except for promoter SNP 8 (p = 0.01). In contrast to Horan 
et al.  [9] , we found that promoter SNP 2 was not polymor-
phic since all patients and controls carried the same al-
lele. In patients and controls, there was a 100% linkage 
disequilibrium between LCR SNP 1 and 2, and there was 
a 100% linkage disequilibrium between promoter SNPs 4 
and 5. Gene structure, sequence variation and linkage 
disequilibrium between LCR and promoter SNPs in our 
patients is shown in  figure 1 . In patients and controls, 
promoter SNP 6 was strongly linked with LCR SNP1 (D’ 
0.96, R 2 0.92;  fig. 1 ). In patients, promoter SNP 6 was 
strongly linked with SNP ‘P1’ in intron 4 of  GH1  (D’ 0.95, 
R 2 0.72; P1 genotypes were not available for controls, see 
methods section).
 Height in cases and controls, and serum IGF-I levels 
in patients were normally distributed. Four promoter 
SNPs were related with height and IGF-I levels. An over-
view of these SNPs, their rs numbers, alleles and their 
relations with clinical parameters are shown in  tables 1 
and  2 , as well as  figure 2 . 
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 Fig. 1. LD plot showing linkage disequilibrium between  GH1 
 LCR, promoter and intronic SNPs. Black squares indicate SNPs 
that are in 100% LD (‘highest possible correlation’) with other 
SNPs. Dark and light gray squares represent lower levels of link-
age disequilibrium, represented by R 2 values in the squares. In the 
schematic representation of the GH1 LCR and promoter, open 
boxes represent binding sites (for PIT1, nuclear factor 1, vitamin 
D response element) and the TATA box, the hatched box with 
ATG represents the transcriptional initiation codon, and num-
bers represent SNP numbers. Prom = Promoter; IVS4_90 = in-
tronic SNP ‘P1’ IVS4 +90 T/A; 0 = 1st base of  GH1 cDNA se-
quence. 
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 Since genotype frequencies and clinical associations 
differed between IGHD patients and controls, we discuss 
the results of the IGHD patients and healthy controls sep-
arately.
 IGHD Patients 
 The study population consisted of 43 male and 19 fe-
male IGHD patients, which is in accordance with a male 
predominance in the overall Dutch IGHD population. 
Mean ( 8 SD) age at testing was 15.6  8 6.4 years, mean 
age at the start of GH treatment was 5.7  8 2.7 years. At 
the start of GH treatment, height SDS was –3.1  8 0.9 and 
IGF-I SDS was –3.3  8 2.3. There were no differences in 
genotype frequencies, height SDS or IGF-I SDS between 
males and females. 
 We found significant differences in height and serum 
IGF-I levels between carriers of the different genotypes at 
individual promoter SNPs 6, 8 and 9 ( table 2 ). LCR SNP1, 
promoter SNP 6 and intron 4 SNP ‘P1’ (IVS4 +90 T/A) 
were highly linked ( fig. 1 ). In our population, there was 
no significant association between the individual intron 
4 SNP and peak GH levels, HSDS and IGF-I levels as
formerly described by Hasegawa et al.  [12] (data not 
shown).
 We did not find any relation between LCR/promoter 
SNPs and the 1st year response to GH treatment (data not 
shown).
 Controls 
 The controls (27 males and 45 females) had a mean ( 8 
SD) age at testing of 21.0  8 1.6 years and height SDS of 
–0.2  8 1.0. There were no differences in genotype fre-
quencies or height SDS between males and females. 
 For promoter SNPs 6 and 11, height differed signifi-
cantly between the carriers of the various genotypes ( ta-
ble 2 ).
 IGHD Patients versus Controls 
 We compared promoter SNP genotypes between 
IGHD patients and controls, and found that homozygos-
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 Fig. 2.  GH1  promoter and LCR SNPs genotyped in this study, the functional regions in which they are located 
and their associations with clinical data (adapted from Horan et al.  [9] ). NF1 = Nuclear factor 1; VDRE = vita-
min D response element. 
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Table 1. SNPs located in the LCR, promoter and intron 4 of GH1
SNP IDa Positionb Reference GH1 allelec Functional region 
LCR SNP 1/2e 1194/1144 rs4968672/rs4968673 G/Af/Tf/Gf PIT1 
LCR SNP 3 990 – C/Tf PIT1 
Prom SNP 1 –476 rs41299065 G/Af
Prom SNP 2 –364 – Gd
Prom SNP 3 –339 rs62636320 G/–f
Prom SNP 4/5e –308/–301 rs1811081/rs2011732 G/Tf
Prom SNP 6 –278 rs2005171 G/Tf NF1
Prom SNP 7 –168 rs2727338 T/Cf
Prom SNP 8 –75 rs11568828 A/Gf PIT1
Prom SNP 9 –57 rs2005172 G/Tf VDR
Prom SNP 10 –31 rs11568827 G/–f TATA
Prom SNP 11 –6 rs6171 A/Gf TSS
Prom SNP 12 –1 rs695 A/Tf/Cf TSS
Prom SNP 13 +3 rs6175 G/Cf TSS
Prom SNP 14 +16 rs9282699 A/Gf 5-UTR
Prom SNP 15 +25 rs6172 A/Cf 5-UTR
Prom SNP 16 +59 rs6173 T/Gf 5-UTR
GH1 SNP P1 IVS4+90 dbSNP 2665802 T/Af Intron 4
TSS = Transcriptional start site; PIT1 = PIT1 binding site; NF1 = nuclear factor 1 binding site; VDR= vita-
min D receptor binding site; Prom = promoter; – = not available. 
a SNP identification according to Horan et al. [9]. b SNP position relative to GH1 transcriptional start site.
c The most frequent genotypes in our study at the various promoter SNP sites are in accordance with the ex-
pected genotype when sequencing GH1 instead of any of the other four GH1 paralogue genes. d Only G alleles 
were reported by Horan et al. [9] and our study. e SNPs are 100% in linkage disequilibrium with each other.
f Minor allele.
Table 2. Frequencies of individual promoter SNPs and their relations with clinical data
IGHD patients Controls
n HSDS IGF-I SDS n HSDS
Promoter SNP 6 GG 22 (37%) –3.3 (0.8) –4.0 (2.6) 19 (27%) 0.3 (0.7)
GT 32 (53%) –3.1 (0.9) –3.0 (2.0) 42 (59%) –0.6 (0.9)
TT 6 (10%) –2.5 (0.8) –1.4 (1.2) 10 (14%) –0.1 (0.8)
T = 37% p = 0.14 p = 0.03 T = 44% p = 0.003
Promoter SNP 8 AA 53 (88%) –3.2 (0.9) –3.4 (2.3) 63 (87%) –0.3 (0.9)
AG 7 (12%) –2.5 (0.7) –2.0 (1.0) 7 (10%) –0.6 (0.8)
GG 0 – – 2 (3%) 0.8 (1.2)
G = 6% p = 0.04 p = 0.14 G = 8% p = 0.16
Promoter SNP 9 GG 25 (42%) –3.1 (0.8) –2.6 (1.6) 25 (35%) –0.2 (0.9)
GT 22 (37%) –3.1 (1.1) –3.0 (2.3) 42 (58%) –0.4 (1.0)
TT 13 (22%)** –3.3 (0.8) –4.8 (2.6) 5 (7%) 0.2 (0.7)
T = 40% p = 0.8 p = 0.02 T = 36% p = 0.41
Promoter SNP 11 AA 24 (40%) –3.2 (0.7) –4.0 (2.5) 18 (25%) 0.0 (1.0)
AG 31 (52%) –3.1 (1.0) –2.9 (2.0) 43 (60%) –0.6 (0.9)
GG 5 (8%) –3.2 (0.7) –2.0 (1.6) 11 (15%) 0.2 (0.9)
G = 34% p = 0.9 p = 0.10 G = 45% p = 0.012
HSDS = height SDS (for patients at start of GH treatment). 
** Homozygosity for the minor allele is more frequent in IGHD patients than in controls, p = 0.005.
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ity for the minor allele of SNP 9 was more frequent among 
patients than among controls (21% vs. 7%, p = 0.005, ta-
ble 2). Since the minor allele at SNP 9 is associated with 
lower IGF-I levels in patients, this suggests this allele 
might contribute to impaired GH levels in IGHD pa-
tients.
 The promoter SNP 12 was tri-allelic with the major al-
lele A occurring in controls in combination with 2 differ-
ent minor alleles (AC and AT, frequencies AA 74%/AT 
19%/AC 5%/TT 1%), whereas in patients, only the AT 
genotype was present. Among controls, there was no dif-
ference in height SDS between individuals with the AC 
and those with the AT genotype.
 For promoter SNP 13, the minor allele was present in 
4 of 72 controls (6%), whereas all 62 patients were homo-
zygous for the major allele (p = 0.124). For the remaining 
SNPs, genotype and allele frequencies were similar for 
patients and controls. 
 Multiple Regression 
 The promoter SNPs that were associated with height 
and/or IGF-I levels in patients or controls (SNPs 6, 8, 9 
and 11) were present in 23 different combinations (‘SNP 
6-8-9-11 genotypes’), of which 7 were present in at least 
5% of the patients or controls ( table 3 ). Only 48 controls 
and 44 patients carried these 7 most frequent combined 
genotypes; clinical data of the patients and controls with 
these genotypes are shown in  table 3 .
 Backward multiple regression showed that the ‘SNP 
6-8-9-11 genotypes’ (numbered 1–7 according to  table 3 ) 
explained 10.8% of the variation in IGF-I SDS in IGHD 
patients (adjusted R 2 0.108, p = 0.02). In controls, the 
‘SNP 6-8-9-11 genotypes’ explained 15.9% of HSDS vari-
ation (R 2 0.159, p = 0.003).
 Discussion 
 We analyzed  GH1  LCR/promoter SNPs in IGHD pa-
tients without mutations or deletions in  GH1  or  GHRHR , 
and examined whether these SNPs were associated with 
height, serum IGF-I levels and response to GH treatment 
in order to explain the phenotypic variability present 
among IGHD patients. We compared patients’ data with 
those of a normal control group and found that homozy-
gosity for the minor allele of SNP 9 was more frequent 
among patients than among controls (21% vs. 7%, p = 
0.005). The minor allele at SNP 9 was associated with low-
er IGF-I levels in patients, suggesting that this allele might 
contribute to impaired GH production in IGHD patients. 
Also SNP 6, 8 and 11 were related with height and IGF-I 
levels. 
 LCR SNPs 1 and 2, promoter SNP 6 and intron 4 SNP 
‘P1’ (IVS4 +90 T/A; only available for IGHD patients) were 
highly linked. However, in contrast to Hasegawa et al. 
 [12] , we did not find any significant association between 
the individual intron 4 SNP and peak GH levels, HSDS, 
Table 3. Frequencies of combined genotypes of promoter SNPs 6, 8, 9 and 11 and their relations with clinical data
SNP 6-8-9-11 genotype* IGHD patients Controls
n1 % height 
SDS
peak GH4 
arginine (mU/l)
peak GH4 
clonidine (mU/l)
IGF-I2 
SDS
n1 % height3 
SDS
1 G/G A/A T/T A/A 12 27.2 –3.2 (0.8) 12.1 (9.2) 9.5 (5.1) –5.0 (2.6) 4 8.3 0.4 (0.5)
2 G/G A/A G/T A/A 5 11.4 –3.5 (0.8) 17.6 (1.3) 15.0 (7.2) –2.1 (2.3) 6 12.5 0.5 (0.8)
3 G/G A/A G/T A/G 0 – – – – – 6 12.5 0.0 (0.9)
4 G/T A/A G/T A/G 12 27.2 –3.2 (1.3) 11.0 (5.1) 12.0 (5.2) –3.7 (2.6) 26 54.2 –0.6 (0.9)
5 G/T A/A G/G A/G 9 20.5 –3.2 (0.8) 9.0 (5.8) 11.5 (5.2) –2.7 (1.2) 5 10.4 –0.5 (0.8)
6 G/T A/G G/G A/G 3 6.8 –3.0 (0.1) 6.5 (5.6) 12.0 (0.1) –2.2 (1.7) 1 2.1 –0.4
7 T/T A/A G/G A/G 3 6.8 –3.0 (0.6) 9.3 (5.2) 10.6 (6.9) –1.3 (0.7) 0 – –
44 100.0 48 100.0
Data are shown as mean (SD). 
* Only genotypes present in at least 5% of the patients or con-
trols are shown. 
1 Difference in genotype frequencies between IGHD patients 
and controls; p = 0.002. 
2 IGF-I SDS difference between genotypes; p = 0.08. 
3 Height SDS difference between genotypes; p = 0.05. 
4 Peak GH levels did not differ significantly between genotypes 
(tested by nonparametric Kruskall-Wallis test due to non-normal 
distribution of the parameters).
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and IGF-I levels in our population (data not shown), 
whereas we did find significant associations between LCR 
SNPs 1 and 2 and growth-related parameters, as well as 
between promoter SNP 6 and these parameters ( fig. 2 ). 
This suggests that the relation between the intron 4 SNP 
and growth-related parameters reported by Hasegawa et 
al. [12] , might actually be caused by its linkage with LCR 
SNPs 1 and 2 or promoter SNP 6, which, in our study, have 
stronger associations with growth-related parameters, 
but were not studied by Hasegawa et al. [12] . 
 We tried to combine promoter SNPs 6, 8, 9 and 11 
into haplotypes. Although the result of the multiple re-
gression based on these combined genotypes should be 
interpreted with caution due to the reduced patient 
number and subsequent power reduction, in our popu-
lation the combined genotypes explained 10.8% of the 
variation in serum IGF-I levels in IGHD patients and 
15.9% of height variation in controls. Although all pa-
tients had IGHD according to Dutch consensus criteria, 
certain genotypes were associated with a relatively mild 
phenotype. 
 The impact of individual SNPs can be explained by the 
fact that the regions in which they are located are impor-
tant for transcription of  GH1 . The LCR contains DNase 
I-hypersensitive sites located at –14.5 to –32 kb relative 
upstream to the  GH1  promoter, where the transcription 
factor PIT1 binds in order to regulate  GH1  transcription. 
Therefore, LCR SNPs may alter transcription of  GH1. 
 SNP 6 is located in the part of the promoter where nucle-
ar factor 1 binds  [33] .  Binding of nuclear factor 1 to the 
nuclear factor 1 binding site is necessary for transcription, 
and variation at this site may alter expression of  GH1 . Pro-
moter SNP 8 is located in the proximal PIT1 binding site 
and promoter SNP 9 is located in the region correspond-
ing to the vitamin D receptor response element. Disturbed 
binding of PIT1 and the vitamin D receptor to the PIT1 
binding site and vitamin D receptor response element, 
respectively, may alter transcription and, thus, expression 
of the  GH1  gene. Both SNP 8 and 9 were shown in vitro 
to interact with nucleic acid binding proteins, and alter-
native alleles exhibit differential protein binding  [9] ; SNP 
9 showed protein interaction only for the G allele, not the 
T allele  [9] . This is in accordance with our findings in vivo 
that patients homozygous for the T allele have very low 
IGF-I levels ( table 2 ). For SNP 8, Esteban et al.  [10] dem-
onstrated a lower HSDS in carriers of the alternate allele 
in a control normal height adult population; Giordano 
demonstrated a diminished transcriptional activity for 
the alternate allele  [11] . For SNP 9, Giordano demonstrat-
ed diminished GH secretion in alternate allele carriers 
 [34] . SNP 11 is located in the transcriptional start site of 
 GH1 ; therefore, variation at this site may alter efficacy of 
transcription, leading to varying levels of  GH1  expres-
sion. Probably, the effect of the promoter SNPs is the sum 
of individual SNP effects and effects based on combina-
tions with other SNPs. Variation at 1 individual SNP site 
can cause altered binding of the corresponding protein. 
This altered binding can in turn affect the binding of a 
2nd protein at another SNP site, but the extent to which 
the binding of this 2nd protein is affected will also depend 
on the variation at the 2nd SNP site. 
 Associations between LCR/promoter SNPs with height 
and IGF-I levels are likely to be mediated by GH levels in 
serum, which may vary due to altered expression of  GH1 . 
Although the variation in IGF-I SDS between the differ-
ent genotypes was largely in accordance with the varia-
tions in peak GH levels obtained during GH stimulation 
tests, the association between the genotypes and peak GH 
levels was not significant ( table 3 ). The fact that IGF-I lev-
els are associated with LCR/promoter SNPs, whereas 
stimulated GH levels are not, may be explained by the fact 
that forced GH secretion during a stimulation test does 
not always reliably reflect the spontaneous GH secretion 
pattern. Due to the fact that it reflects spontaneous daily 
GH secretion, serum IGF-I is considered a more reliable 
indicator of spontaneous GH secretion than GH peaks 
during stimulation tests  [35–37] . Therefore, although 
LCR/promoter SNPs are not significantly related to peak 
GH levels obtained during stimulation tests, the relation 
of these SNPs with height and IGF-I levels is probably 
mediated by altered spontaneous GH secretion. 
 The LCR/promoter SNP genotype frequencies and 
clinical associations differed between IGHD patients and 
healthy controls. These differences may be explained by 
the fact that certain genotypes could be beneficial for 
processes that take place in IGHD patients, but not in 
controls, due to the altered GH/IGF-I status. 
 Although all controls had a height within the normal 
range, the lowest height SDS were found in patients het-
erozygous for promoter SNPs 6 and 11. This association 
with shorter stature was specific for the heterozygous 
state, since controls homozygous for the minor allele had 
a higher HSDS. The finding that the heterozygous state 
is associated with a certain phenotype and differs from 
the 2 homozygous states, has been previously reported 
and is the subject of research and discussion  [9, 38–47] . 
Heterozygous advantage or disadvantage of promoter 
SNPs may be explained by allele-dependent regulation of 
gene expression. A key process in allele-dependent regu-
lation of gene expression is trans - regulation, which means 
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